2023
-
Thank you for making the 2023 SABCS® a success
The 2023 SABCS® was a huge success, with record attendance and number of submitted abstracts. The premier symposium for breast cancer research, care, and advocacy had plenty of new features, as well as the robust science that is the meeting’s hallmark.
-
Year in Review summarizes important developments in breast cancer from 2023
Heide L. Ford, PhD; Jennifer K. Richer, PhD; Ann Partridge, MD, MPH; and Mariana Chavez Mac Gregor, MD, MSC, FASCO, outlined updates across the spectrum of breast cancer research and clinical practice.
-
Panelists highlight what they learned, next steps in View from the Trenches
Experts reviewed the updates from the 2023 SABCS® that may have an immediate impact for patients and physicians.
-
Tumor-agnostic therapies advance possibilities for precision medicine
Vivek Subbiah, MD, and fellow panelists explored how genomics are driving a new era of tumor-agnostic therapies for cancer in which drugs are approved for biomarkers rather than cancer types.
-
Friday General Session features late-breaking data from KATHERINE and INAVO120 clinical trials
Findings from 11 studies were presented Friday during the third and final General Session of the 2023 SABCS®.
-
AACR Outstanding Investigator outlines need for better metastatic breast cancer models
Alana L. Welm, PhD, on Friday discussed what she was doing to model metastatic breast tumors using patient-derived xenografts and organoids, and she implored her fellow researchers to work together to advance the field.
-
Panelists explore challenging, unresolved breast cancer questions based on real-world case studies
Audience members brought real-world clinical cases and concerns before a multidisciplinary panel on Thursday, prompting discussions about choosing optimal care and treatment for patients with breast cancer in routine practice.
-
SABCS Snippets: Update on antibody-drug conjugates
Aditya Bardia, MD, breast medical oncologist at Massachusetts General Hospital, and Saba Shaikh, MD, breast medical oncologist at Mays Cancer Center at UT Health San Antonio, discuss antibody-drug conjugates.
-
SABCS Snippets: DESTINY-Breast08
Komal Jhaveri, MD, clinical director for early drug development service at Memorial Sloan Kettering Cancer Center, and Saba Shaikh, MD, breast medical oncologist at Mays Cancer Center at UT Health San Antonio, discuss the DESTINY-Breast08 trial.
-
SABCS Snippets: Fusion RNAs
Nolan Priedigkeit, MD, PhD, medical oncology fellow at Dana-Farber Cancer Institute, and Andrew Brenner, MD, professor of medicine and breast medical oncologist at Mays Cancer Center at UT Health San Antonio, discuss fusion RNAs and metastatic breast cancer.